Elaboration of host P2X₇R-P₃₈MAPK axis involvement against intracellular leishmania donovani by Spergulin-A: a comprehensive study

Niladri Mukherjee ^{a*}, Saswati Banerjee ^{a*}, Sk. Abdul Amin^b, Tarun Jha^b, Sriparna Datta^c, Krishna Das Saha^{a*}

^aCancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata-700032, India

^bNatural Science Laboratory, Department of Pharmaceutical Technology, Division of Medicinal & Pharmaceutical Chemistry, P. O. Box 17020, Jadavpur University, Kolkata, India.

^cDepartment of Chemical Technology, University of Calcutta, Kolkata 700009, India

Email address: krishna@iicb.res.in (Krishna Das Saha); ^{*} Equal contribution,

*Corresponding Author

26 Current drugs are inadequate for the treatment of visceral leishmaniasis an
 27 immunosuppressive ailment caused by *Leishmania donovani*. Regrettably, there is no
 28 plant-origin antileishmanial drug present. P2X₇R is constitutively present on
 29 macrophage surfaces and can be a putative therapeutic target in intra-macrophage
 30 pathogens with function attributes towards inflammation, host cell apoptosis, altered
 31 redox and phagolysosomal maturation by activating p₃₈MAPK. Here we demonstrated
 32 that the initial interaction of Spergulin-A, a triterpenoid saponin with macrophages was
 33 mediated through P2X₇R involving the signaling cascade intermediates Ca⁺⁺,
 34 P₃₈MAPK, and NF-κβ. P₃₈MAPK involvement shown to have specific and stern
 35 importance in leishmanial killing with increased NF-κBp65. Phago-lysosomal
 36 maturation by Spergulin-A also campaigns for another contribution of P2X₇R. In vivo
 37 evaluation of the anti-leishmanial activity of Spergulin-A was monitored through
 38 P2X₇R, P₃₈MAPK, and NF-κβ in murine spleen and bone-marrow macrophages and
 39 advocated Spergulin-A of being a natural compound of leishmanicidal functions which
 40 acted through the P2X₇R-P₃₈MAPK axis.

41

42

43

44

45

46

47

48

49

50 The obligate intra-macrophage parasite *Leishmania donovani* causes the sternest form of
 51 leishmaniasis (visceral) and if left untreated can reach casualty as high as 100% within 2 years
 52 of infection in developing countries.¹ VL is widespread in tropical and temperate areas and is
 53 endemic in 100 countries with an approximate yearly occurrence of 500,000 cases, of which
 54 70,000 people expire every year.² Miltefosine, Sodium antimony gluconate, Pentamidine, and
 55 Amphotericin B are applied as the choice of chemotherapeutics, however, reported occasions
 56 of toxicity or resistance.³ *Leishmania* parasites have developed various successful strategies for
 57 the manipulation of parental activities of macrophage-like antigen presentation, nitric oxide
 58 intermediates, and oxygen radical generation and cytokine production.⁴ Despite elaborate
 59 literature on leishmanial host-pathogen interaction, there is scope for an explicit revelation of
 60 compound mediated distortion of intracellular signaling cascades that can subvert parasite
 61 propagation and multiplication and can advise new therapeutic stratagems.

62 Botanicals or phytochemicals have proven their worth as potent therapeutics and are
 63 applied as medication against different and various types of human and animal ailments.
 64 However, unluckily VL remains an exception even after serious efforts from different groups
 65 of scientists and drug companies.⁵ Reports of potent plant-derived anti-leishmanial agents are
 66 there in the literature,⁶ however, mostly performed against the vector-borne promastigote form
 67 of the parasite.⁷ Our previous effort demonstrated that triterpenoid saponin, Spergulin-A,
 68 isolated from a perennial shrub *Glinus oppositifolius* is a potent intracellular antileishmanial
 69 compound besides being an immune-modulator.⁵ Scientific documentation in this particular
 70 area of interest also publicized that triterpenoid saponin of *Careya arborea* and some water-
 71 insoluble saponin acted as potent leishmanicidal agents.⁸⁻¹⁰

72 P2X₇R (a purinergic receptor) is constitutively present on macrophage surfaces with
 73 function attributes towards inflammation, apoptosis and intracellular pathogen control.¹¹
 74 Modulation of macrophage biology in respect to P2X₇R expression alteration is monitored in

75 *Leishmania amazonensis* and other intracellular pathogens like *Toxoplasma*, *Brucella*
 76 *Cryptosporidium* and *Microsporidia*.¹²⁻¹⁶ P2X₇R over-expression can be a putative
 77 chemotherapeutic strategy in intra-macrophage pathogens. P2X₇R expression is positively
 78 correlated with inflammation, host cell apoptosis, generation of ROS and NO as well as
 79 phagolysosomal maturation;¹¹ all are different strategies for intra-macrophage pathogen killing
 80 and absence or underexpression of the P2X₇R have been found with underachieved
 81 intracellular pathogen control.¹¹ Existing literature suggests that activation of P2X₇R can
 82 trigger mitogen-activated protein kinases (MAPKs), including P₃₈MAPKs.¹⁷

83 Activation of p₃₈MAPK in respect to the P2X₇R over-expression leads to the generation
 84 of ROS and NO through NADPH oxidase is also mentioned in the literature^{18,19} and embrace
 85 consequence in intra-MΦ pathogen control strategies which also comprises leishmanial
 86 parasites. Regulation of iNOS expression in macrophages is managed by MAPK signaling
 87 molecules with closely associated with NF-κB activation.²⁰ It was reported that P₃₈MAPK can
 88 phosphorylate Rab5 an important step in the endosome maturation process and critical in
 89 intracellular leishmanial killing²¹ and our previous finding denoted that P₃₈MAPK
 90 phosphorylation was decisively responsible for maturation of phagolysosomal complexes and
 91 subsequent leishmanicidal activity.² Importance of MAPKs in establishment and maintenance
 92 of their infection also favoured by the fact that viscerotropic *L. donovani* parasites alleviate
 93 MAPK phosphorylation and thus cut of the MAPK signaling cascades towards possible
 94 leishmanicidal outcome in naive murine bone marrow-derived macrophages²² with NF-κB
 95 being the prime transcription factor in NO production²³ with evidence that P₃₈MAPK activation
 96 is crucial in *L. donovani* infection abolition.²⁴ Phagosome-lysosome fusion is also an important
 97 innate-effector immune response of host macrophages the process of which is maintained by
 98 sequential acquisition and removal of different proteins of hydrolases and peptidases in nature
 99 and aided in degrading intracellular pathogens which includes leishmanial parasites.²⁵ The

phagolysosome fusion is also critically acquainted by enhanced P2X₇R expression and managed through bivalent calcium ion efflux and RhoA-Phospholipase D controlled pathway.¹¹

Screening compounds toward purinergic receptor modifications have identified structurally diversified compounds over two thousand and almost one-third of them are being natural products having an affinity towards these receptors. As for example teniposide, a semi-synthetic podophyllotoxin derivative can inhibit P2X₇R, whereas, agelasine and garcinolic acid,²⁶ potentially activate the same. In recent years efforts are made towards the identification of compounds that can modulate P2X receptors aiming towards novel chemotherapeutic measurements towards diseases associated with inflammation.^{27,28} Extracts of the traditional Chinese medicinal plant, *Panax ginseng* can also activate P2X₇²⁹ which further identified ginsenosides, triterpenoid saponins found in the root extract of plants for P2X₇R activation properties.³⁰ Conversely, the *R. longifolia* extract and fractions found to have an inhibitory effect on the P2X₇R leading to their anti-inflammatory function.³¹ Additionally, there are ample reports of triterpenoid saponins interacting with different groups of MAPKs including P₃₈MAPK in conferring their cytotoxic or protective roles.³²

To explore the molecular insights in depicting the intracellular leishmanicidal function of the triterpenoid saponin Spergulin-A, we have emphasized on the involvement of P2X₇R and downstream pathways involved. We checked the *in silico* binding affinity of Spergulin-A with P2X₇R. P2X₇R blockage having a hindrance towards the reduction of Spergulin-A mediated leishmanial killing strongly advocates for its association and significance. Involvement of P₃₈MAPK shown to have specific and stern importance in leishmanial killing as with increased NF-κBp65 mediated ROS and NO production reciprocal with parasite reduction and this phenomenon also secondarily established by simultaneous expression analysis of P₃₈MAPK and Gp91-phox, NADPH oxidase family member. Phago-lysosomal maturation promotion in mediating intracellular leishmanial killing by Spergulin-A also

campaigns for another contribution of P2X₇R as well as multipotent effectiveness of Spergulin-A of being a natural product supposed to act like. Finally, the in vitro observation was clarified in vivo for Spergulin-A of being a natural compound of leishmanicidal functions and acted through the P2X₇R- P₃₈MAPK axis.

Results

Involvement of the P2X₇ receptor in mediating intracellular anti-leishmanial activity of Spergulin-A. At the commencement of the evaluation of antileishmanial affectivity of Spergulin-A against RAW 264.7 MΦ internalized parasites, increasing doses of Spergulin-A (Fig. 1a) was applied for 24 h. Spergulin-A was found to be efficient against the intercellular parasites in a dose-dependent manner; however above 30μg/mL of doses, the antileishmanial activity reached a plateau. Therefore, we have selected the dose of 30μg/mL for a detailed assessment of the intracellular anti-leishmanial activity of Spergulin-A. In our previous report, we had also elaborated that this dose is also perfectly safe against the host RAW 264.7 MΦs and that Spergulin-A was not effective against the acellular promastigote or intermediate axenic amastigote forms of *L. Donovanii* at diverse dose applied dose range.⁵

Use of Brilliant Blue G (BB-G) as a selective P2X₇R antagonist³³ was adequate in literature against both in vivo³⁴ and in vitro systems³⁵. Different IC₅₀ values for different cell lines had been reported in the literature and also against a related mouse macrophage cell line (J774.G8) with applied dose range well within 10 μM,^{35,36} however not conclusive against RAW 264.7 MΦs. We evaluated the dose range for RAW 264.7 MΦ survival in accordance with the view of the dose range application for its inhibitory purposes against P2X₇R (Fig. 1b). The dose 10μM of BB-G was selected as P2X₇R antagonist in this study to be applied in vitro against RAW 264.7 MΦs as about 92% of the exposed cells were alive after 24 h (Fig. 1b) and the dose is well within the accepted P2X₇R antagonist range in literature.

Thereafter, the contribution of P2X₇R in intracellular *L. donovani* infection and Spergulin-A mediated leishmanicidal function was thoroughly examined (Fig. 1c, d, e). Co-expression of CFSE-tagged *L. donovani* and subsequent P2X₇R expression was monitored by FACS during infection and Spergulin-A (30µg/mL) treatment, with or without BB-G, the P2X₇R antagonist (Fig. 1c i-vi). P2X₇R expression was highest in the treated panel with expected lowest CFSE-tagged *L. Donovani* existence and application of BB-G in treatment panel lowered both the P2X₇R expression and *L. Donovani* removal. Spergulin-A treatment exhibited a significant rise of P2X₇R expressing MΦs of about 44.3% of the parent population in connection with intracellular parasite removal. Whereas, all other panels P2X₇R expressing MΦs were about or below 5% of the parent population with or without BB-G application (Fig. 1c i-vi). And it was also noticed that P2X₇R antagonist BB-G application significantly lowered Spergulin-A mediated intracellular *L. Donovani* removal (Fig. 1c iv-vi) and thus avow important role of P2X₇R in Spergulin-A activated the intracellular leishmanicidal function.

The dose-dependent implication of Spergulin-A in intracellular leishmanial removal and subsequent aversion by BB-G application which resulted in P2X₇R blockage was monitored (Fig. 1d). In all the applied Spergulin-A doses, it was observed that BB-G application lowered the leishmanicidal property of Spergulin-A significantly. Confocal micrographs of CFSE-tagged intracellular *L. donovani* with subsequent P2X₇R expression were monitored for Spergulin-A treatment as well as BB-G application (Fig. 1e). It was obvious from the micrographs that Spergulin-A treatment was able to increase P2X₇R expression and intracellular *L. Donovani* removal whereas the application of the P2X₇R antagonist resulted in profuse existence of the parasite despite the Spergulin-A treatment (Fig. 1e).

This experimental evidences suggested that Spergulin-A mediated its intracellular leishmanicidal action with close assistance with P2X₇R and subsequent signaling pathways linked with over-expression of P2X₇R. Therefore, downstream signaling intermediates

associated with P2X₇R should be closely monitored for accessing the precise involvement of P2X₇R in Spergulin-A mediated leishmanial killing.

Spergulin-A treatment has effects on the P2X₇ receptor-dependent intracellular Ca⁺⁺ release. It is documented that P2X₇R activation can lead to Ca⁺⁺ influx and resulted in mycobacterial removal.³⁷ This Ca⁺⁺ influx is definitely of great consequence in case of intracellular leishmanial killing as this increased Ca⁺⁺ titer is linked with phagolysosomal fusion, P₃₈MAPK activation and increased release of NO and ROS along with the altered release of pro and anti-inflammatory cytokines; all of them have leishmanicidal function actively or passively. Thus it is important to monitor the Ca⁺⁺ influx during Spergulin-A treatment and also link the event with P2X₇R activation. A set of FACS analyses with P2X₇R and Ca⁺⁺ corresponding to Fura2M was expressed both graphically and through histograms of fluorescence index and percentage of cells expressing the P2X₇R and Ca⁺⁺ for normal, *L. donovani* parasitized, different doses of Spergulin-A treated MΦs both BB-G exposed and unexposed (Fig. 2a-c). Mean fluorescence index equivalent of the expressions of both P2X₇R and Ca⁺⁺ was significantly higher in Spergulin-A treated panels and that too in a dose-dependent manner compared to either normal or infected MΦs, and with the application of BB-G, both these expressions got lowered compared to the corresponding BB-G unexposed panels (Fig. 2b). Subsequently, the percentage of P2X₇R and Ca⁺⁺ expressing cells against the parent population also higher for the treated panels and the application of P2X₇R agonist BB-G not only lowered the P2X₇R expressing population but also have diminishing the effect on Ca⁺⁺ expressing cells (Fig. 2c). These results strongly advocated the involvement and dependence between P2X₇R expression and Ca⁺⁺ influx in Spergulin-A mediated anti-leishmanial function.

P₃₈MAPK expression alteration affects Spergulin-A mediated anti-leishmanial activity with P2X₇ receptor involvement. The involvement of P₃₈MAPK was evaluated in *L. donovani* infection headway and also the effect of Spergulin-A with the involvement of

P₃₈MAPK towards infection riddance as analyzed by flow cytometry (Fig. 3a). Apart from the panels where P₃₈MAPK inhibitor (SB203580) was used (Fig. 3a iv-vi) almost all the cells were expressing P₃₈MAPK either infected or treated with Spergulin-A (Fig. 3a i-iii). The difference lies in the expression level of P₃₈MAPK. Compared to the control MΦ panel, infection with *L. donovani* comprehensively reduced P₃₈MAPK (Fig. 3a ii and vii). However, Spergulin-A treatment increased the P₃₈MAPK intensity (Fig. 3a iii and vii) and thus possibly has a very precise correlation with the reduced intracellular parasitic count as when SB203580 was used parasitic count also decreased along with the P₃₈MAPK expression (Fig. 3a v-vii).

Co-expression analyses of P2X₇R and P₃₈MAPK were evaluated by confocal microscopy (Fig. 3b). For the control MΦs, both the expressions of P2X₇R and P₃₈MAPK were at a basal level and for the infected and infected with BB-G their expression were down-regulated more precisely P₃₈MAPK expression. Whereas, in the Spergulin-A treated panel both P2X₇R and P₃₈MAPK were visually overexpressed several folds (Fig. 3b) in accordance with the anti-leishmanial effect demonstrated previously. However, the application of BB-G, the P2X₇R antagonist lowered the expression of P₃₈MAPK. Inhibitor mediated underexpression of P₃₈MAPK in the treated panels demonstrated compromised intracellular parasite removal (Fig. 3a) and confocal micrographs (Fig. 3b) suggested that P2X₇R activation can positively regulate P₃₈MAPK expression and most importantly both of them are essential in intracellular Spergulin-A mediated the anti-leishmanial effect of which P₃₈MAPK act downstream of P2X₇R.

NF-κBp65 expression alteration in Spergulin-A mediated leishmanicidal activity.

Likewise, the connection of NF-κB in Spergulin-A mediated infection control was also monitored (Fig. 3c). The trend was almost alike of P₃₈MAPK expression, parasitic infection down-regulated the expression altitude of NF-κB and Spergulin-A treatment was noticed to up-regulate their expression when applied in the infection panel and in this case also the inhibitor

(Curcumin) were noticed to down-regulate NF- κ B expressions with moderate increase of the parasitic load even when co-applied with Spergulin-A (Fig. 3c vi, vii).

ROS and NO participate in anti-leishmanial effects of Spergulin-A. Changes in the production of ROS as well as NO in respect to *L. donovani* infection and Spergulin-A treatment was measured by flow cytometry (Fig. 4a, b) and confocal micrographs (Fig. 4c) with the aid of fluorescent dyes DCFDA and DAF-2 DA respectively. It was observed that ROS production was downregulated with respect to *L. donovani* infection and got up-regulated in MΦs with Spergulin-A (30 μ g/mL). In comparison to infected MΦs, Spergulin-A (30 μ g/mL) exposure elevated ROS production in the infected MΦs (Fig. 4a iv, vi) which is in the alignment of the lessened parasite load in them (Fig. 4c). However, when NAC has applied the ROS abrogation (Fig. 4a v, vi) also leads to substantial loss of the parasiticidal activity of Spergulin-A (Fig. 4c).

Spergulin-A (30 μ g/ml) treatment was found to encourage the NO production in the infected MΦs (Fig. 4b v, vii). It was found that the NO production has a positive effect in checking the parasite load inside the MΦs as NMMA application in the Spergulin-A treated infected MΦs reduced the effectivity of the compound (Fig. 4b vi, Fig. 4c) and strongly support the anti-parasitic activity is regulated by NO.

Expression alteration of p-P₃₈MAPK, p-NF- κ Bp65, and Gp91-phox in intervening ROS and NO involvement of Spergulin-A mediated anti-leishmanial effect. Gp91-phox the glycosylated subunit of the heterodimer phagocytic NADPH oxidase flavocytochrome b558, plays a crucial role in regulating the redox status of MΦs and thus can serve as a marker of the alteration of oxidative stress due to Spergulin-A treatment in the infected MΦs, aimed towards an explanation of the parasitic burden alteration treated with it at different doses. Spergulin-A at different doses (10, 20 and 30 μ g/mL) applied in the infected MΦs and levels of Gp91-phox was evaluated for both p-P₃₈MAPK and NF- κ Bp65 (Rel A) positive MΦs as

evaluated by both FACS (Fig. 5a) and confocal microscopy (Fig. 5b) (for only p-P₃₈MAPK). Gp91-phox expression was simultaneously up-regulated with increasing doses of Spergulin-A along with the increment of p-P₃₈MAPK expression (Fig. 5a i-v (upper panels) and Fig. 5a vi). Likewise, Gp91-phox expression was also found to be elevated with respect to NF-κBp65 expression along with Spergulin-A in a dose-dependent manner (Fig. 5a i-v (lower panels) and Fig. 5a vii).

Confocal images provided substantial evidence that with the increasing doses Spergulin-A boosted p-P₃₈MAPK expression and also Gp91-phox expression simultaneously (Fig. 5b). Infection with *L. donovani* lowered both p-P₃₈MAPK and Gp91-phox expression in them compared to the control (Fig. 7b).

Phago-lysosomal maturation promotion by Spergulin-A in respect to its anti-leishmanial activity. Phagolysosomal maturation considered a significant process to chuck out the intracellular pathogens of phagocytic cells and the pathogens promoted multiple ways to evade this sequential process. Spergulin-A mediated dynamics of Rab 5 an early phagosomal marker and CathepsinD, a late phagosomal marker was observed by confocal microscopy (Fig. 6a). *L. donovani* infection was found to suppress these markers compared to the control MΦs. Whereas, the dose-dependent application of Spergulin-A found to amplified both Rab5 and CathepsinD expression and signified the occurrence of phagolysosomal fusion and demonstrated a key role of this event during leishmanicidal property arbitrated by Spergulin-A (Fig. 6a).

In Vivo Evaluation of anti-leishmanial activity of Spergulin-A in lights of P₃₈-MAPK and P2X₇ receptor involvement. Evaluation of the intracellular anti-leishmanial activity of Spergulin-A in vitro against RAW 264.7 MΦs strongly favored the involvement of P2X₇R activation and subsequent participation of P₃₈MAPK and NF-κBp65 downstream. Therefore an in vivo evaluation of the anti-leishmanial activity of Spergulin-A with a demonstration of the

expression alteration analyses of the aforementioned key mediators could have positively linked ours in vitro observations with its leishmanicidal affectivity in vivo. After treatment schedule (Control and Treated group received 30mg/kg b.wt. of Spergulin-A for every alternate day for 10 doses) was over mice were sacrificed and spleen and bone marrow MΦs were harvested for each group and evaluated by flow cytometry for the linked expressions of P2X₇R-P₃₈MAPK and P2X₇R-NF-κBp65 against spleen MΦs (Fig. 6b) and for P2X₇R-P₃₈MAPK against bone marrow MΦs (Fig. 6c).

From the observations made against spleen MΦs the mean fluorescence index values for P2X₇R against both the experiments showed that the treated panels showed highest P2X₇R activation and which was found to be least for the infected panels (Fig. 6b vii, viii) and subsequent expressions of P₃₈MAPK (Fig. 6b vii) and NF-κBp65 (Fig. 6b vii) showed the same pattern; highest for the treated panels. However, for the Bone marrow MΦs although P2X₇R expression was highest in the treated panel (Fig. 6c iii, iv), P₃₈MAPK expression in the treated panel was less than the infected panel (Fig. 6c ii, iv) which slightly differs from our all previous observations both in vitro and in vivo combined.

The in vivo findings confirmed the in vitro findings and were perfectly in accordance of the pathway of action speculated from the in vitro findings combined for the intracellular activity evaluation of Spergulin-A; precisely with the involvement of P2X₇R, Ca⁺⁺ influx, P₃₈MAPK, NF-κBp65, ROS, NO and phagolysosomal maturation being the key mediators sequentially. A graphical presentation of the step-wise anti-leishmanial activity propagation by Spergulin-A has been demonstrated in Fig. 7d.

In silico binding assessment of Spergulin A with P2X₇ Receptor. The possible binding mode of Spergulin A with its putative target P2X₇ was analysed by *in silico* methods. Molecular docking study was employed to check the binding mode of investigated compound i.e., Spergulin A toward target P2X₇ (PDB: 5U1X). The molecular docking result illustrates few

hydrogen bonding interactions between the Spergulin A and P2X₇ receptor as shown in Fig. 7a. The docked conformation of Spergulin A with P2X₇ indicates that the sulfonyl function interact with Gln116, Trp167 (Fig. 7b). The amino acid residue Arg295 is found to form another hydrogen bonding interaction with the oxygen atom of pyran nucleus (Fig. 7c). Moreover, it is also noticed that the non-sugar part of Spergulin A is exposed to solvent accessible surface area of the receptor.

Discussion

Leishmaniasis is a poorly investigated disease mainly affecting people in countries that are developing and with challenged health practices. *Leishmania* living within the harsh environment of phagocytes has developed strategies for prompt physiological adaptation, escape from first-line defense systems and ability to inhibit a number of host cell functions.³⁸ To endure and blossom inside macrophages *Leishmania* adopt various strategies to modulate its physiology and signal kinetics. The direct influence of the parasite to the macrophages linked to the suppressed generation of nitric oxide and oxidative burst and also their inhibitory biological.^{39,40} Indirectly, *Leishmania* influences the antigen presentation and T cell tasks in a way that macrophage deactivation guides towards parasite endurance mainly by amendment of host cell signaling of different kinases and phosphatases.⁴¹ Being the host cell for the parasite, any modulation of the macrophages also has an effect on the immune system and thus helping their survival by overall immunomodulation of the host. Our previous effort⁵ demonstrated that *G. oppositifolius* and an isolated triterpenoid saponin, Spergulin-A was inconsistent of direct leishmanicidal effect of against promastigotes and axenic amastigotes however proved to be a potent intracellular antileishmanial mediator besides being an immune-modulator measured in vitro in RAW 264.7 MΦs those infected with an *L. donovani* virulent strain. This observation opens for the scope for precise demonstration of the pathways involved in its intracellular anti-

leishmanial effect and involvement and possible activation of P2X₇R has been considered. P2X₇R reported being constitutively expressed on MΦ surfaces and also reported to be associated with signaling cascades of inflammation, apoptosis and subsequent intracellular pathogen control.¹¹ Additively, intracellular anti-leishmanial attributes of Spargulin-A demonstrating the involvement of the purinergic receptor P2X₇ also hypothesized on the reports of compounds screened towards the purinergic receptor amendments that about one-third of the structurally diversified compounds are being natural products with a proven affinity towards these purinergic receptors.⁴²

Reduction of Spargulin-A mediated intra-MΦ leishmanial count was found to be linked with P2X₇R activation and this reduction was hindered with P2X₇R antagonist BB-G application and thus confirmed P2X₇R involvement and importance (Fig. 1a-e). Existing literature suggested that P2X₇R possibly contributes to the removal of intracellular parasites namely *Chlamydia*, *Leishmania*, *Toxoplasma*,^{43,44} and *Mycobacterium tuberculosis* by mediating strong pro-inflammatory and cytotoxic activity.⁴⁵ P2X₇R receptor activation was found to be helpful in reducing *L. amazonensis* parasitic load in macrophages via leukotriene B₄ (LTB₄) production.⁴⁶ Interestingly enough, P2X₇ knock out mice were observed to possess increased lesion size and the parasitic load of *L. amazonensis* with an unwarranted CD4⁺ T cell proliferation.⁴⁷

P2X₇R activation with extracellular stimuli like ATP can initiate opening of cation-specific ion channel and result in the influx of Ca⁺⁺ and the efflux of K⁺ and with extended exposure able to create pores in the plasma membrane resulted in the passage of larger molecules.¹¹ Our experimental verification confirmed Spargulin-A activated P2X₇R mediated Ca⁺⁺ influx (Fig. 2) and unleashed a key mediator in intracellular leishmanial control.

Changes in the concentration of intracellular Ca²⁺ and PI3K activity are essential for proper phagosomal maturation.⁴⁸ Ca⁺⁺ is a key second messenger and cytosolic build-up of

Ca⁺⁺ can lead to synaptic transmission, macrophage activation and apoptosis.⁴⁹ More interestingly, the cytosolic Ca⁺⁺ concentration affects the phagosomal maturation process by modulating membrane fusion between phagosomes and lysosomal vesicles by activating phospholipase D via RhoA, which can ultimately perish intracellular pathogens like *Leishmania*⁵⁰ this phagolysosomal fusion can also mediated by regulating the activities of two Ca²⁺-dependent effector proteins, calmodulin and the multifunctional serine/threonine-protein kinase CaMKII.⁵¹ Spergulin-A mediated phagolysosomal maturation was confirmed in the treated parasitized MΦs (Fig. 6a) by examining co-expression of early Rab5 and late CathepsinD phagolysosomal markers in the treated cells and provided confirmation of the event in intracellular parasite control.

An influx of Ca⁺⁺ can activate the P₃₈MAPK, which in turn stimulates a number of downstream effector signaling cascades.⁵² The connection of phosphorylated P₃₈MAPK and leishmanial removal was closely monitored with Spergulin-A treatment (Fig. 3a, b). With infection p-P₃₈MAPK level lowered and treatment with Spergulin-A resulted in elevated p-P₃₈MAPK and diminished intracellular parasite count which again reversed with P₃₈MAPK inhibitor application and thus one can conclude from the results the close association of P₃₈MAPK activation and leishmanial control. The same observation pattern was elaborated for NF-κBp65 (Fig. 3c) wherewith the application of inhibitor compromised Spergulin-A mediated intracellular parasite control with associated NF-κBp65 down-expression. Existing reports also suggested that impaired P₃₈MAPK expression during host-parasite interaction at the primary hours proven beneficial during subsequent *L. donovani* infection establishment²⁴ also P₃₈MAPK inactivation by *Leishmania* parasites can lead to the iNOS inhibition and inferior NO production.³⁹ Host invasion by intra-macrophage pathogens is frequently associated with the restraining of NF-κBp65 total levels in infected macrophages, and this reduction, in turn, can modulate the gene expressions necessary during the normal

immunological clearance of the parasites from the host cells.⁵³ Phosphorylated P₃₈MAPK also promotes the association of NADPH oxidase at the cell membrane and resulted in production and release of superoxide (O₂⁻),⁵⁴ enhanced NF-κBp65 activation lead to the ensuing transcription of inducible nitric oxide synthase (iNOS) and production of nitric oxide (NO),⁵⁵ as well as production of tumour necrosis factor (TNF) and IL-6.² Spergulin-A was monitored to activate Gp91-phox, a glycosylated subunit of NADPH oxidase flavocytochrome b558 and also a marker of the NOX activity⁵⁶ with subsequent upregulated p-P₃₈MAPK and p-NF-κBp65 expression (Fig. 5).

Enhanced production of ROS after P2X₇R activation is well recognized in MΦs,⁵⁷ mediated by NOX2 additionally also augment mitochondrial ROS.⁵⁸ *Leishmania* parasites inside macrophages acclimatize various intimidating conditions during blood transmission, and ROS and RNS by host macrophages.⁵⁹ At the onset of leishmanial infection, superoxide production resulted from the oxidative burst due to phagocytosis⁶⁰ and later NO is produced after activation of macrophages by IFN-γ and TNF⁶¹ resulting in abolition of intracellular parasites.⁶² The active subversion of ROS and NO production due to leishmanial infection was noticed to be minimized during Spergulin-A treatment and application of their abrogators minimized the anti-leishmanial effect of the compound (Fig. 4) and thus signifies the importance of ROS and NO in intracellular parasite removal.

Meanwhile, a molecular docking study was performed to get a primary idea about the binding interaction between Spergulin A and its putative target P2X₇. Few hydrogen bonding interactions are observed between Spergulin A and amino acids at allosteric site binding of P2X₇ (PDB: 5U1X). The docked conformation of Spergulin A with P2X₇ indicates the non-sugar part of Spergulin A is exposed to solvent accessible surface area.

Finally, in vitro results from activity evaluation of Spergulin-A mediated intracellular anti-leishmanial effect was directed to the inference that P2X₇R-P₃₈MAPK activation is the

key mediator of the said action with the downstream involvement of Ca^{++} regulated ROS, NO and phagolysosomal fusion as the effector cascade. A flow diagram of which was depicted in Fig. 7d. Additionally, in vivo evaluation in determining the effect of Spergulin-A also established the fact that $\text{P2X}_7\text{R}$ and P_{38}MAPK expression was evidently upregulated (Fig. 7a-c) and confirmed the in vitro findings.

Methods

Materials. Cell culture medium, Roswell Park Memorial Institute-1640 (RPMI-1640) and M-199, fetal bovine serum (FBS), penicillin-streptomycin (PS), and HEPES were acquired from Gibco BRL, Grand Island, NY, USA. Tissue culture plastic wares were acquired from NUNC (Roskilde, Denmark) and DAPI (4',6-diamidino-2-phenylindole dihydrochloride), LysoTracker Red, CFSE and FURA 2-AM from Invitrogen, CA. Primary antibodies, secondary antibodies, and inhibitors were obtained from Santa Cruz Biotechnology, Santa Cruz, CA and Cell signaling technologies, USA.

Macrophages. Murine macrophage ($\text{M}\Phi$) cell line RAW 264.7 (American Type Culture Collection, Rockville, MD) was cultured in Roswell Park Memorial Institute medium 1640 (RPMI-1640), supplemented with 10% heat-inactivated FBS and 100 $\mu\text{g}/\text{ml}$ of antibiotic (penicillin-streptomycin).

Parasites. Pathogenic *Leishmania donovani* [MHOM/IN/1983/AG83] infection was maintained by the passage in BALB/c mice. *L. donovani* promastigotes, attained from infected BALB/c mice spleen were cultured in complete M199 media (10% FBS, pH 7.4, 100U/ml penicillin G sodium, 100 $\mu\text{g}/\text{ml}$ streptomycin sulfate, 25 mM HEPES, sodium bicarbonate (2.2g/L), 10% FBS and 1% Pen Strep (pH - 7.2-7.4) at 22°C. All pathogen and animal-related works were performed according to prior approval from Institutional Biosafety Committee, CSIR-Indian Institute of Chemical Biology (CSIR IICB/IBSC/CERT-32/18-19) and CSIR-

IICB-Animal Ethics Committee (IICB/AEC/Meeting/Oct/ 2017), respectively. The care and maintenance of animals were done in agreement with the Committee for the Purpose of Control And Supervision of Experiments on Animals (CPCSEA), guidelines.

Parasite infection and treatment. A ratio of 1:10 (MΦs: parasite) was used to infect macrophages with *L. donovani* promastigotes. MΦs were incubated with parasites for 4 h, washed with PBS, and either fresh media was added or treated with inhibitors for the required time. To study the anti-leishmanial activity, normal and infected macrophages were treated with Spargulin-A at effective concentrations up to 72 h. Miltefosine used as a positive anti-leishmanial reference.

FACS and Confocal microscopy with CFSE tagged *L. donovani*. MΦs were parasitized with CFSE-tagged promastigotes (25 μM/1×10⁶ promastigotes in 1 ml media for 30 min) and subjected to treatment with Spargulin-A (10, 20, 30 μg/ml) for 24 h.

For confocal microscopy, MΦs (1×10⁵/glass coverslips) were washed twice with PBS after infection and treatment, then fixed in chilled 70% ethanol. The nuclei were stained with DAPI and observed under Olympus Fluoview FV10i confocal microscope with a 60X objective lens. For FACS, MΦs (1×10⁵/well in a six-well plate) were rinsed twice with PBS after infection and treatment, harvested by scraping, resuspended in 400 μl PBS, and analyzed by BD FACS LSR Fortessa with excitation at 494 nm and emission at 518 nm.

Measurement of Phospho-P₃₈MAPK, Gp91-phox, Phospho-NF-κBp65. For phospho-P₃₈MAPK and Phospho-NF-κBp65 determination control, infected, and treated cells were washed with PBS, then fixed with 70% ethanol, after perforation with Triton-x 100 solution (0.5%) labeled with primary and respective fluorochrome conjugated antibodies. 20μM of SB203580 was used to inhibit p-P₃₈MAPK and 25 μM of curcumin for was used as A p-NF-κBp65 inhibitor with the necessary time of incubation periods. For the measurement of Gp91-phox, the above procedures were followed with specific primary and secondary antibodies.

Cells were then analyzed in BD FACS LSR Fortessa.

Measurement of P2x7 with BBG. To determine P2X₇ level control, infected, and treated cells were washed with PBS, then fixed with 70% ethanol, after perforation with Triton-x 100 solution (0.5%) labeled with primary and respective fluorochrome conjugated antibodies. Before treatment with Spargulin-A, cells were treated with 10μM of Brilliant Blue G (BBG) to inhibit P2X₇ in macrophage cells for 24 h of the incubation period.

Confocal Microscopy. After fixation with 70% ethanol and perforation, MΦs were stained with primary and fluorochrome conjugated secondary antibody. Then slides were mounted and nuclei were stained with DAPI in case of translocation of p-P₃₈MAPK, P2X₇, and Gp91-phox. To study the leishmanicidal activity, CFSE was used to stain *L. donovani* and Lysotracker was used to monitor acidic organelles in cells. Rab5 and CathepsinD were stained using primary and respective fluorochrome conjugated secondary antibodies. All specimens were observed under an Olympus Fluoview FV10i confocal microscope with a 60X objective lens.

Measurement of calcium release. Treated and untreated MΦs were collected, after washing twice with PBS, treated with FURA 2 AM (Molecular Probes) at 37°C. After 45 min of incubation, the cells were washed with PBS, resuspended in fresh PBS, and examined by BD FACS LSR Fortessa with an excitation wavelength of 380 nm and an emission wavelength of 510 nm.

FACS analyses of intracellular ROS and NO. Intracellular ROS was monitored based on the transform in fluorescence of H₂DCFDA. DAF-2 DA was used to perceive intracellular NO.⁵ Briefly, after infection and treatment, MΦs were scrapped and incubated in PBS containing 7.0 μM DAF-2DA (at 37°C for 30 min) or 20 μM DCF-DA (at 37°C for 15 min) and evaluated by BD FACS LSR Fortessa with excitation at 480 nm and emission at 515 nm for both.

In vivo leishmanicidal activity. To study leishmanicidal activity, parasite burdens in the spleen and bone marrow of control and Spargulin-A treated mice were determined. After

confirmation of the *L. donovani* infection in the BALB/c and given an adequate time of the infection propagation in vital organs like liver, spleen and bone marrow, infected mice were divided into two groups arbitrarily with one control group. For phospho-P38 MAPK, phospho-NF- κ Bp65 and P2X₇ protein determination, control and treated primary cells were stained using primary and fluorochrome conjugated secondary antibodies. Then Cells were then analyzed by BD FACS LSR Fortessa with respective excitation and emission wavelength.

In silico analysis. Molecular docking study^{63,65} was employed to check the binding mode of the investigated compound toward its putative target P2X₇R. Chem 3D ultra 8.0.3 (Chem 3D Pro Version 8.0 And Chem Draw Ultra Version 8.0) software was used to construct the three-dimensional structure of the investigated compound.⁶⁶ The energy minimization of the compound was done by molecular orbital package (MOPAC) module with 100 iterations and a minimum RMS gradient of 0.10.⁶⁴ The preparation of the ligand structure prior to docking is performed by incorporating polar hydrogen atoms along with Gasteiger partial charges. The torsions are allowed to rotate during docking.⁶⁷

The crystallographic structures of P2X₇ (PDB: 5U1X) were used for this analysis.⁶⁸ The macromolecules were prepared by using Discovery Studio 3.0.⁷⁰ Polar hydrogen atoms were added to the protein by using the AutoDock Tools (ADT).⁷¹ The grid box was selected 5U1X centered at the corresponding ligand crystal structure by maintaining a spacing of 1 Å.⁶⁴ Finally, the docking was performed by using the AutoDock Vina.⁷² The docked poses were visualized in Discovery Studio 3.0.⁷⁰

Statistical analysis. All experimental values were denoted as mean $\pm$ SEM acquired from at least three replicate experiments. Statistical significance and variations among groups were evaluated with One-Way analysis of variance (ANOVA) followed by Dunnett's test. P values $\leq$ 0.05 (*) or $\leq$ 0.01 (**) were considered as indicative of significance.

References

1. Tiuman, T.S., Santos, A.O., Ueda-Nakamura, T., Filho, B.P. & Nakamura, C.V. Recent advances in leishmaniasis treatment. *Int. J. Infect. Dis.* **15**, e525–e532 (2011).
2. Banerjee, S. et al. Attenuated *Leishmania* induce pro-inflammatory mediators and influence leishmanicidal activity by p38 MAPK dependent phagosome maturation in *Leishmania donovani* co-infected macrophages. *Sci. Rep.* **6**, 22335 (2016).
3. Alvar, J. et al. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One* **7**, e35671 (2012).
4. Freitas, E.O., Leoratti, F.M.S., Freire-de-Lima, C.G., Morrot, A. & Feijó, D.F. The contribution of immune evasive mechanisms to parasite persistence in visceral leishmaniasis. *Front. Immunol.* **7**, 153 (2016).
5. Banerjee, S. et al. Intracellular anti-leishmanial effect of Spergulin-A, a triterpenoid saponin of *Glinus oppositifolius*. *Infect. Drug Resist.* **12**, 2933–2942 (2019).
6. Oryan, A. Plant-derived compounds in treatment of leishmaniasis. *Iran. J. Vet. Res.* **16**, 1–19 (2015).
7. Kaur, H., Thakur, A. & Kaur, S. Immunoprophylactic potential of a cocktail of three low molecular weight antigens of *Leishmania donovani* along with various adjuvants against experimental visceral leishmaniasis. *Iran. J. Parasitol.* **13**, 11–23 (2018).
8. Mandal, N. et al. A triterpenoid saponin possessing antileishmanial activity from the leaves of *Careya arborea*. *Phytochemistry* **67**, 183–190 (2006).
9. Delmas, F. et al. Antileishmanial activity of three saponins isolated from ivy, a-hederin, b-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro. *Planta Med.* **66**, 343–347 (2000).

10. Maes, L. et al. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant *Maesa balansae* against visceral leishmania species. *Antimicrob. Agents Chemother.* **48**, 130–136 (2004).
11. Miller, C.M. et al. The Role of the P2X7 Receptor in Infectious Diseases. *PLoS Pathog.* **7**, e1002212 (2011).
12. Aga, E. et al. Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite *Leishmania major*. *J. Immunol.* **169**, 898–905 (2002).
13. Lees, M.P. et al. P2X7 receptor-mediated killing of an intracellular parasite, *Toxoplasma gondii* by human and mouse macrophages. *J. Immunol.* **184**, 7040–7046 (2010).
14. Eskra, L., Mathison, A. & Splitter, G. Microarray analysis of mRNA levels from RAW 264.7 macrophages infected with *Brucella abortus*. *Infect. Immun.* **71**, 1125–1133 (2003).
15. Liu, J., Enomoto, S., Lancto, C.A., Abrahamsen, M.S. & Rutherford, M.S. Inhibition of apoptosis in *Cryptosporidium parvum*-infected intestinal epithelial cells is dependent on surviving. *Infect. Immun.* **76**, 3784–3792 (2008).
16. del Aguila, C. et al. *Encephalitozoon microsporidia* modulates p53-mediated apoptosis in infected cells. *Int. J. Parasitol.* **36**, 869–876 (2006).
17. Chen, S. et al. P2X7 receptor antagonism inhibits p38 MAPK activation and ameliorates neuronal apoptosis after subarachnoid hemorrhage in the rat. *Crit. Care Med.* **41**, e466-74. (2013).
18. Pfeiffer, Z.A. et al. Nucleotide receptor signalling in murine macrophages is linked to reactive oxygen species generation. *Free Radic. Biol. Med.* **42**, 1506–1516 (2007).
19. Gavala, M.L., Pfeiffer, Z.A. & Bertics, P.J. The nucleotide receptor P2RX7 mediates ATP-induced CREB activation in human and murine monocytic cells. *J. Leukoc. Biol.* **84**, 1159–1171 (2008).

- 544 20. Lee S.H. et al. Fucofuroeckol-A from *Eisenia bicyclis* inhibits inflammation in
545 lipopolysaccharide-induced mouse macrophages via downregulation of the MAPK/NF- κ B
546 Signaling Pathway. *J. Chem.* **2016**, 6509212 (2016).
- 547 21. Cavalli, V. et al. The stress induced MAP kinase p38 regulates endocytic trafficking via
548 GDI:Rab5 complex. *Mol. Cell.* **7**, 421–432 (2001).
- 549 22. Prive, C. & Descoteaux, A. *Leishmania donovani* promastigotes evade the activation of
550 mitogen-activated protein kinases p38, c-Jun N-terminal kinase, and extracellular signal-
551 regulated kinase-1/2 during infection of naive macrophages. *Eur. J. Immunol.* **30**, 2235–
552 2244 (2000).
- 553 23. Jeong, H.J. et al. Inhibition of TNF- α and IL-6 production by Aucubin through
554 blockade of NF- κ B activation RBL-2H3 mast cells. *Cytokine* **18**, 252–259 (2002).
- 555 24. Junghae, M. & Raynes, J. G. Activation of p38 mitogen-activated protein kinase attenuates
556 *Leishmania donovani* infection in macrophages. *Infect. Immun.* **70**, 5026–5035 (2002).
- 557 25. Gutierrez, M.G. Functional role(s) of phagosomal Rab GTPases. *Small GTPases* **4**, 148–
558 158 (2013).
- 559 26. Fischer, W., Urban, N., Immig, K., Franke, H. & Schaefer, M. Natural compounds with
560 P2X7 receptor-modulating properties. *Purinergic Signal.* **10**, 313–326 (2014).
- 561 27. Bartlett, R., Stokes, L. & Sluyter, R. The P2X7 receptor channel: recent developments and
562 the use of P2X7 antagonists in models of disease. *Pharmacol. Rev.* **66**, 638–675 (2014).
- 563 28. Stokes, L., Layhadi, J.A., Bibic, L., Dhuna, K. & Fountain, S.J. P2X4 Receptor Function
564 in the Nervous System and Current Breakthroughs in Pharmacology. *Front Pharmacol.* **8**,
565 291 (2017).
- 566 29. Helliwell, R.M. et al. Selected ginsenosides of the protopanaxdiol series are novel positive
567 allosteric modulators of P2X7 receptors. *Br. J. Pharmacol.* **172**, 3326–3340 (2015).

30. Orioli, E., De Marchi, E., Giuliani, A.L. & Adinolfi, E. P2X7 Receptor Orchestrates Multiple Signalling Pathways Triggering Inflammation, Autophagy and Metabolic/Trophic Responses. *Curr Med Chem.* 24, 2261-2275 (2017).
31. Santos, J.A.A. et al. Effect of *Rheedia longifolia* Leaf Extract and Fractions on the P2X₇ Receptor *In Vitro*: Novel Antagonists? *J. Med. Food* **14**, 920-929 (2011).
32. Podolak, I., Galanty, A. & Sobolewska, D. Saponins as cytotoxic agents: a review. *Phytochem. Rev.* **9**, 425–474 (2010).
33. Peng, W. et al. Systemic administration of an antagonist of the ATP-sensitive receptor P2X₇ improves recovery after spinal cord injury. *Proc. Natl. Acad. Sci. USA* **106**, 12489–12493 (2009).
34. Wang, X.H., Xie, X., Luo, X.G., Shang, H. & He, Z.Y. Inhibiting purinergic P2X₇ receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease. *Mol. Med. Rep.* **15**, 768–776 (2017).
35. Soares-Bezerra, R.J. et al. An Improved Method for P2X₇R Antagonist Screening. *PLoS ONE* **10**, e0123089 (2015).
36. Namovic, M.T., Jarvis, M.F. & Donnelly-Roberts, D. High throughput functional assays for P2X receptors. *Curr. Protoc. Pharmacol.* Chapter 9:Unit 9 15 (2012).
37. Biswas, D. et al. ATP induced autophagy is associated with rapid killing of intracellular mycobacteria within human monocytes/macrophages. *BMC Immunol.* **9**, 35 (2008).
38. Freitas, E.O., Leoratti, F.M.S., Freire-de-Lima, C.G., Morrot, A. & Feijó, D.F. The contribution of immune evasive mechanisms to parasite persistence in visceral leishmaniasis. *Front. Immunol.* **7**, 153 (2016).

- 591 39. Olivier, M., Gregory, D.J. & Forget, G. Subversion mechanisms by which *Leishmania*
592 parasites can escape the host immune response: a signaling point of view. *Clin. Microbiol.*
593 *Rev.* **18**, 293–305 (2005).
- 594 40. Van Assche, T., Deschacht, M., da Luz, R.A., Maes, L. & Cos, P. Leishmania-macrophage
595 interactions: insights into the redox biology. *Free Radic. Biol. Med.* **51**, 337–351(2011).
- 596 41. Soulat, D. & Bogdan, C. Function of macrophage and parasite phosphatases in
597 Leishmaniasis, *Front Immunol.* **8**, 1838 (2017).
- 598 42. Fischer, W., Urban, N., Immig, K., Franke, H. & Schaefer, M. Natural compounds with
599 P2X7 receptor-modulating properties. *Purinergic Signal.* **10**, 313–326 (2014).
- 600 43. Coutinho-Silva, R. et al. Inhibition of chlamydial infectious activity due to P2X7R-
601 dependent phospholipase D activation. *Immunity* **19**, 403–412 (2003).
- 602 44. Coutinho-Silva, R. & Ojcius, D.M. Role of extracellular nucleotides in the immune
603 response against intracellular bacteria and protozoan parasites. *Microbes Infect.* **14**, 1271–
604 1277 (2012).
- 605 45. Amaral, E.P. et al. Pulmonary infection with hypervirulent Mycobacteria reveals a crucial
606 role for the P2X7 receptor in aggressive forms of tuberculosis. *PLoS Pathog.* **10**, e1004188
607 (2014).
- 608 46. Chaves, S.P. et al. Modulation of P2X7 purinergic receptor in macrophages by *Leishmania*
609 *amazonensis* and its role in parasite elimination. *Microbes Infect.* **11**, 842–849 (2009).
- 610 47. Figliuolo, V.R. et al. The role of the P2X7 receptor in murine cutaneous leishmaniasis:
611 aspects of inflammation and parasite control. *Purinergic Signal.* **13**, 143–152 (2017).
- 612 48. Nunes, P. & Demaurex, N. The role of calcium signaling in phagocytosis. *J. Leukoc. Biol.*
613 **88**, 57–68 (2010).
- 614 49. Pinton, P., Giorgi, C., Siviero, R., Zecchini, E. & Rizzuto, R. Calcium and apoptosis: ER-
615 mitochondria Ca²⁺ transfer in the control of apoptosis. *Oncogene* **27**, 6407–6418 (2008).

50. Moradin, N. & Descoteaux, A. *Leishmania* promastigotes: building a safe niche within macrophages. *Front. Cell Infect. Microbiol.* **2**, 121 (2012).
51. Swulius, M.T. & Waxham M.N. Ca(2+)/calmodulin-dependent protein kinases. *Cell Mol. Life Sci.* **65**, 2637–2657 (2008).
52. Corre, I., Paris, F. & Huot, J. The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. *Oncotarget.* **8**, 55684–55714 (2017).
53. Calegari-Silva, T.C. et al. NF-κB-mediated repression of iNOS expression in *Leishmania amazonensis* macrophage infection. *Immunol. Lett.* **127**, 19–26 (2009).
54. Tarafdar, A. & Pula G. The role of nadph oxidases and oxidative stress in neurodegenerative disorders. *Int. J. Mol. Sci.* **19**, 3824 (2018).
55. McAdam, E. et al. Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are important mediators of reflux-induced cell signalling in esophageal cells. **33**, 2035–43 (2012).
56. Yu, L., Quinn, M.T., Cross, A.R. & Dinauer, M.C. Gp91(phox) is the heme binding subunit of the superoxide-generating NADPH oxidase. *Proc. Natl. Acad. Sci. USA.* **95**, 7993–7998 (1998).
57. Lenertz, L.Y., Gavala, M.L., Hill, L.M. & Bertics, P.J. Cell signaling via the P2X(7) nucleotide receptor: linkage to ROS production, gene transcription, and receptor trafficking. *Purinergic Signal.* **5**, 175–187 (2009).
58. Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nat. Immunol.* **12**, 222–230 (2011).
59. Carneiro, P.P. et al. The role of nitric oxide and reactive oxygen species in the killing of *Leishmania braziliensis* by monocytes from patients with cutaneous leishmaniasis. *PLoS ONE* **11**, e0148084 (2016).

60. Almeida, T.F., Palma, L.C., Mendez, L.C., Noronha-Dutra, A.A. & Veras, P.S. *Leishmania amazonensis* fails to induce the release of reactive oxygen intermediates by CBA macrophages. *Parasite Immunol.* **34**, 492–498 (2012).
61. Gantt, K.R. et al. Oxidative responses of human and murine macrophages during phagocytosis of *Leishmania chagasi*. *J. Immunol.* **167**, 893–901 (2001).
62. Bogdan, C., Rollinghoff, M. & Diefenbach A. The role of nitric oxide in innate immunity. *Immunol. Rev.* **173**, 17–26 (2000).
63. Amin, S.A. et al. Pharmacoinformatics study of piperolactam a from Piper beetle root as new lead for nonsteroidal anti fertility drug development. *Comput. Biol. Chem.* **67**, 213–224 (2017a).
64. Amin, S.A., Adhikari, N., Agrawal, R.K., Jha, T. & Gayen, S. Possible Binding Mode Analysis of Pyrazolo-triazole Hybrids as Potential Anticancer Agents through Validated Molecular Docking and 3D-QSAR Modeling Approaches. *Lett. Drug Des. Discov.* **14**, 515–527 (2017b).
65. Bhardwaj, B. et al. Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer. *SAR QSAR Environ. Res.* **30**, 457–475 (2019).
66. Chem 3D Pro Version 8.0 And Chem Draw Ultra Version 8.0 Are Software Programs Developed by Cambridge Soft Corporation. USA.
67. Lv, P.C. Li, H.Q., Sun, J., Zhou, Y. & Zhu, H.L. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents. *Bioorg. Med. Chem.* **18**, 4606–4614 (2010).
68. <https://www.rcsb.org/structure/5UIX>: <https://www.rcsb.org/structure/5UIX> (as accessed on 14th August 2019)

69. Karasawa, A. & Kawate, T. Structural basis for subtype-specific inhibition of the P2X₇ receptor. *Elife*. **5**, e22153 (2016).
70. Discovery Studio 3.0 (DS 3.0), Accelrys Inc., CA, USA, 2015.
71. Autodock Tools 1.5.6 (ADT)/MGL Tools 1.5.6, The Scripps Research Institute, CA, USA, 2012. Available at <http://mgltools.scripps.edu>
72. Trott, O. & Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **31**, 455–461 (2010).

Acknowledgments

Sincere thanks are given to the Science and Engineering Research Board (SERB), Govt. of India (Grant No. [PDF/2016/001437](#) and [EMR/2015/001674](#)) for financial support. The manuscript has been critically checked by the full version of the Grammarly software and Urkund for language corrections and plagiarism.

Author contributions

N.M., K.D.S., and S.B. conceptualize the work, N.M., and S.B. acquired, analyzed and written the biological data. S.A.A. and T.J. acquired and analyzed the in silico binding assay data. N.M., S.B. and SAA wrote the manuscript. N.M., T.J, S.D., and K.D.S. supervised the work.

Figure Captions

Fig. 1 Evaluation of P2X₇ receptor involvement in the intracellular anti-leishmanial activity of Spergulin-A. **a** Spergulin-A reduces intracellular *L. donovani* expressed as the number of parasites/20 MΦs dose-dependently after 24 h of treatment with miltefosine as positive control expressing its LC₅₀ and LC₉₀ values. **b** RAW 264.7 MΦ survivability in accordance with the P2X₇ receptor antagonist BB-G application after 24 h. **c** FACS monitored co-expression

analyses of CFSE-tagged *L. donovani* and subsequent P2X₇R expression during infection and
Spergulin-A (30µg/mL) treatment. **d** Bar diagram of Spergulin-A mediated intracellular
leishmanial parasite removal and subsequent aversion by BB-G (10µM) application expressed
as the number of parasites/20 MΦs. **e** Confocal micrographs of consequent expression of
CFSE-tagged intracellular *L. donovani* with P2X₇R expression during Spergulin-A (30µg/mL)
and BB-G (10µM) application. Spergulin-A enhanced P2X₇R expression and intracellular *L.*
Donovani removal, whereas, BB-G caused reversal of the Spergulin-A mediated intracellular
parasite removal and P2X₇R over-expression. Scale bars, 10 µm. Images are representative of
three separate experiments. All values are expressed as mean ± SEM from triplicate assays
from three independent experiments (*P*-values ≤0.05 (*) or ≤0.01 (**)) vs infected panel except
for **b**, where the reference is the RAW 264.7 MΦs; ns denotes not significant).

Fig. 2 FACS monitored Ca⁺⁺ influx evaluation with P2X₇R expression analyses of *L. donovani*
parasitized, Spergulin-A and BB-G exposed MΦs by Fura2M. **a** FACS analyses with P2X₇R
expression and Ca⁺⁺ corresponding to Fura2M. The four quadrants represent different stages of
P2X₇R and Ca⁺⁺ expressing populations, i.e. Q1 (only P2X₇R expressing), Q2 (both P2X₇R and
Ca⁺⁺ expressing), Q3 (double negative) and Q4 (only Ca⁺⁺ expressing). **b** Mean fluorescence
index values equivalent of the expressions of both P2X₇R and Ca⁺⁺ during *L. donovani*
infection, Spergulin-A treatment, and BB-G application. **c** Percentage of P2X₇R and Ca⁺⁺
expressing RAW 264.7 MΦ cells against the parent population during *L. donovani* infection,
Spergulin-A treatment and BB-G application. Images are representative of three separate
experiments. All values are expressed as mean ± SEM from triplicate assays from three
independent experiments (*P*-values ≤0.05 (*) or ≤0.01 (**)) vs infected panel).

Fig. 3 P₃₈MAPK expression alteration with P2X₇ receptor involvement during Spergulin-A
treatment. **a** Flow cytometric analyses of p-P₃₈MAPK expression alteration towards *L.*
donovani infection, Spergulin-A treatment and P₃₈MAPK-inhibitor (SB203580) application

and their co-dependence in Spergulin-A mediated anti-leishmanial effect with the histogram of mean fluorescence values of p-P₃₈MAPK and CFSE-tagged intracellular *L. donovani* in respective populations. **b** Confocal micrographs of co-expression analyses of P2X₇R and P₃₈MAPK in *L. donovani* parasitized, Spergulin-A and BB-G exposed MΦs. Scale bars, 10 μm. **c** NF-κBp65 expression alteration with P2X₇ receptor involvement during Spergulin-A treatment. Flow cytometric analyses of NF-κBp65 expression alteration towards *L. donovani* infection, Spergulin-A treatment and NF-κB-inhibitor (Curcumin) application and their co-dependence in Spergulin-A mediated anti-leishmanial effect with the histogram of mean fluorescence values of NF-κBp65 and CFSE-tagged intracellular *L. donovani* in respective populations. Images are representative of three separate experiments. All values are expressed as mean ± SEM from triplicate assays from three independent experiments (*P*-values ≤0.05 (*) or ≤0.01 (**)) vs infected panel).

Fig. 4 a Evaluation of changes in ROS production in control, infected, and Spergulin-A (30 μg/mL) treated MΦs with H2DCFDA by FACS with or without NAC. **b** Intracellular NO production alterations were also examined with fluorescent probe DAF-2 DA in control, infected, and Spergulin-A (30 μg/mL) treated MΦs by FACS with or without NMMA. **c** Changes in CFSE-tagged intracellular *L. donovani* parasites were micrographed with respect to Spergulin-A treatment and co-application of NAC and NMMA for evaluation of ROS and NO involvement in Spergulin-A mediated anti-leishmanial effect by confocal microscopy, scale bars, 10 μm. Images are representative of three separate experiments. All values are expressed as mean ± SEM from triplicate assays from three independent experiments (*P*-values ≤0.05 (*) or ≤0.01 (**)) vs infected panel).

Fig. 5 Co-expression alteration of p-P₃₈MAPK and Gp91-phox, p-NF-κBp65 and Gp91-phox in Spergulin-A mediated anti-leishmanial effect. **a** Spergulin-A at different doses (10, 20 and 30 μg/mL) applied in the infected MΦs found to elevate levels of Gp91-phox for p-P₃₈MAPK

positive MΦs as evaluated by FACS. Histograms of percent parent populations for p-P₃₈MAPK positive MΦs and both Gp91-phox and p-P₃₈MAPK for different infected and Spargulin-A treated populations denoted their inter-connections. Spargulin-A at different doses (10, 20 and 30µg/mL) applied in the infected MΦs found to elevate levels of Gp91-phox for NF-κBp65 (Rel A) positive MΦs as evaluated by FACS. Histograms of percent parent populations for NF-κBp65 positive MΦs and both Gp91-phox and NF-κBp65 for different infected and Spargulin-A treated populations denoted their inter-connections. **b** Confocal microscopy elaborated that Gp91-phox expression was simultaneously up-regulated with increasing doses of Spargulin-A along with the increment of p-P₃₈MAPK expression. Images are representative of three separate experiments, scale bars, 10 µm. All values are expressed as mean ± SEM from triplicate assays from three independent experiments (*P*-values ≤0.05 (*) or ≤0.01 (**)) vs infected panel).

Fig. 6 a Dynamics of phagolysosomal maturation in demonstrating the dose-dependent anti-leishmanial effect of Spargulin-A. Early phagosome marker Rab-5 expression got upregulated in the treated panel with respect to the control and infected panels. Cathepsin-D (Late phagolysosomal marker) expression also got upregulated with the exposure of Spargulin-A and signifies the phagolysosomal maturation process. Images are representative of three separate experiments, scale bars, 10 µm. **b** In vivo evaluation of the anti-leishmanial effect of Spargulin-A with P₃₈-MAPK and P2X₇ receptor involvement. Graphical presentation of the in-vivo treatment schedule and observation parameters. After confirmation of the *L. donovani* infection in the BALB/C mice, infected mice were divided into two groups arbitrarily with one control group. Control and treated groups received 30mg/kg b.wt. of Spargulin-A for every alternate day for 10 doses then sacrificed and spleen and bone marrow MΦs were harvested after treatment schedule and examined for P2X₇R, p-P₃₈MAPK and NF-κBp65 expression. Mice from each group were sacrificed and spleen MΦs were harvested for each group and evaluated

by flow cytometry for the linked expressions of P2X₇R-p-P₃₈MAPK and P2X₇R-NFκBp65. Mean fluorescence index values equivalent of the expressions of both P2X₇R- p-P₃₈MAPK and P2X₇R-NFκBp65 from spleen MΦs of different experimental mice groups. **c** Mice from each group were sacrificed and bone marrow MΦs were harvested from each group and evaluated by flow cytometry for the linked expressions of P2X₇R-p-P₃₈MAPK. Mean fluorescence index values equivalent of the expressions of both P2X₇R- p-P₃₈MAPK from bone marrow MΦs of different experimental mice groups. Images are representative of three separate experiments. All values are expressed as mean ± SEM from triplicate assays from three independent experiments (*P*-values ≤0.05 (*) or ≤0.01 (**)) vs infected panel).

Fig. 7 In-silico docking study of the interdependence of Spergulin-A with P2X₇ receptor. **a** The proposed interaction investigated compound Spergulin-A with the P2X₇ receptor. The green-colored stick is the inbound crystal compound. **b** The proposed 3D interaction investigated compound Spergulin-A with the amino acid residues of the P2X₇ receptor. **c** The proposed 2D interaction investigated compound Spergulin-A with the amino acid residues of the P2X₇ receptor. **d** A graphical presentation of the step-wise anti-leishmanial activity propagation by Spergulin-A.

c

a

b

c